NCT05580991View on ClinicalTrials.gov

Intratumoral CAN1012(selective TLR7 Agonist) in Subjects with Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

September 9, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Solid Tumor
Interventions
DRUG

CAN1012

CAN1012 IT injection (once every 4 weeks)

Trial Locations (1)

510535

Canwell Biotech Limited, Guangzhou

Sponsors
All Listed Sponsors
lead

Canwell Biotech Limited

INDUSTRY

NCT05580991 - Intratumoral CAN1012(selective TLR7 Agonist) in Subjects with Solid Tumors | Biotech Hunter | Biotech Hunter